Short Bowel Syndrome - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 61 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Short Bowel Syndrome - Pipeline Review, H2 2016, provides an overview of the Short Bowel Syndrome (Gastrointestinal) pipeline landscape.

Short bowel syndrome is a complex disease that occurs due to the physical loss or the loss of function of a portion of the small and/or large intestine. Symptoms include bloating, cramping, fatigue, heartburn, vomiting, weakness and diarrhea. Complications of short bowel syndrome include malnutrition, peptic ulcers, kidney stones and small intestinal bacterial overgrowth. Treatment includes vitamin and mineral supplements, antibiotics, proton pump inhibitors and bile-salt binders.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Short Bowel Syndrome - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Short Bowel Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Short Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Short Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 1 and 5 respectively.Short Bowel Syndrome.

Short Bowel Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Short Bowel Syndrome (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Short Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Short Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Short Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Short Bowel Syndrome (Gastrointestinal)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Short Bowel Syndrome (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Short Bowel Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Short Bowel Syndrome Overview 7
Therapeutics Development 8
Pipeline Products for Short Bowel Syndrome - Overview 8
Short Bowel Syndrome - Therapeutics under Development by Companies 9
Short Bowel Syndrome - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Short Bowel Syndrome - Products under Development by Companies 13
Short Bowel Syndrome - Companies Involved in Therapeutics Development 14
Ardelyx Inc 14
Naia Ltd 15
Nutrinia Ltd 16
OxThera AB 17
Sancilio & Company Inc 18
Shire Plc 19
Tasly Pharmaceutical Group Co Ltd 20
Zealand Pharma AS 21
Short Bowel Syndrome - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
glepaglutide - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
GXG-8 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
NB-1001 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
NB-1002 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
NTRA-9620 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Oxabact - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
RDX-98940 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
SC-403 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
teduglutide - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Short Bowel Syndrome - Dormant Projects 46
Short Bowel Syndrome - Discontinued Products 47
Short Bowel Syndrome - Product Development Milestones 48
Featured News & Press Releases 48
Nov 29, 2016: Naia Rare Diseases Announces Investigational New Drug Application Submission to Initiate Clinical Trials of NB 1001 for Short Bowel Syndrome 48
Jul 07, 2016: Shire Receives Extension of Market Authorization in Europe for Revestive (Teduglutide) for the Treatment of Paediatric Patients with Short Bowel Syndrome (SBS) 48
May 27, 2016: Shire Receives Positive CHMP Opinion in Europe for Revestive (Teduglutide) for Paediatric Patients with Short Bowel Syndrome 49
Feb 15, 2016: Zealand doses the first patients with ZP1848 for short bowel syndrome, advancing the second of its proprietary specialty medicines into Phase II development in 2016 50
Oct 20, 2015: NAIA Rare Diseases a subsidiary of NAIA, Receives Orphan Drug Designation from U.S. FDA for NB1001 for the Treatment of Short Bowel Syndrome 51
Oct 12, 2015: Naia Successfully Completes Pre-IND Meeting with U.S. FDA for NB1001, Long-Acting GLP-1 Receptor Agonist for Treatment of Short Bowel Syndrome 51
Sep 17, 2015: Zealand advances its proprietary, long-acting GLP-2 analogue, ZP1848, into clinical Phase II development for the treatment of Short Bowel Syndrome 52
Apr 06, 2015: Shire Comments on USPTO Petition Related to GATTEX 53
Nov 24, 2014: Teduglutide Granted Orphan Drug Designation in Japan 53
Sep 23, 2014: Oxabact Granted EMA Orphan Drug Designation for Treatment of SBS 54
Jun 30, 2014: FDA Approves Updated Labeling for Gattex (Teduglutide) for Injection to Include Long-Term Data 54
Jan 02, 2014: NPS Pharmaceuticals Initiates Global Registration Study of Teduglutide in Pediatric Patients with Short Bowel Syndrome 55
Nov 13, 2013: NPS Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Gattex for Injection 56
Oct 14, 2013: New Data from STEPS 2 Support the Long Term Use of Gattex for Injection in Adult Patients with Short Bowel Syndrome 57
Oct 02, 2013: NPS Pharmaceuticals Reports Gattex STEPS 2 Study to be Presented at American College of Gastroenterology Meeting 58
Appendix 60
Methodology 60
Coverage 60
Secondary Research 60
Primary Research 60
Expert Panel Validation 60
Contact Us 60
Disclaimer 61

List of Tables

Number of Products under Development for Short Bowel Syndrome, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Short Bowel Syndrome - Pipeline by Ardelyx Inc, H2 2016 14
Short Bowel Syndrome - Pipeline by Naia Ltd, H2 2016 15
Short Bowel Syndrome - Pipeline by Nutrinia Ltd, H2 2016 16
Short Bowel Syndrome - Pipeline by OxThera AB, H2 2016 17
Short Bowel Syndrome - Pipeline by Sancilio & Company Inc, H2 2016 18
Short Bowel Syndrome - Pipeline by Shire Plc, H2 2016 19
Short Bowel Syndrome - Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2016 20
Short Bowel Syndrome - Pipeline by Zealand Pharma AS, H2 2016 21
Assessment by Monotherapy Products, H2 2016 22
Number of Products by Stage and Target, H2 2016 24
Number of Products by Stage and Mechanism of Action, H2 2016 26
Number of Products by Stage and Route of Administration, H2 2016 28
Number of Products by Stage and Molecule Type, H2 2016 30
Short Bowel Syndrome - Dormant Projects, H2 2016 46
Short Bowel Syndrome - Discontinued Products, H2 2016 47